In this webinar, Bryan Ennis, Chief Quality Officer at Sware, and Jeff Brittain, former Head of IT, North America at Bayer and current Managing Director of Emerging Technologies & Workforce Development at the FedEx Institute of Technology, explore how pharma leaders can separate real AI value from industry hype—without compromising GxP and compliance requirements.
During the session, Bryan and Jeff share expert insights and real-world perspectives on which AI capabilities are delivering measurable impact in regulated environments today, which investments are falling short, and how to evaluate emerging technologies through a compliance-first lens. They discuss practical frameworks for assessing AI risk, aligning innovation with quality standards, and making confident, future-ready investment decisions.
Pharma executives, quality and validation leaders, and digital transformation owners: watch the recording to gain actionable guidance on implementing AI responsibly—while protecting product quality, patient safety, and regulatory integrity.
